Epidemiological characteristics of hepatitis c infection in Nizhny Novgorod at the first stage of infection control program (2016–2021)

Abstract

Objective. To characterize the peculiarities of the epidemic process of viral hepatitis C in Nizhny Novgorod at the first stage of the infection control program (2016–2021).

Materials and Methods. A retrospective analysis of the incidence of registered forms of HCV infection in Nizhny Novgorod was carried out using information of statistical and analytical materials. A total of 78 883 blood serum samples were collected from individuals undergoing pre-hospital screening and admitted to non-infectious hospitals from 2016 to 2021. Laboratory testing included the determination of HCV infection markers: anti-HCV IgM and IgG, antibodies to structural and non-structural proteins (n = 2953). Seropositive samples were tested for the presence of HCV RNA (n = 467) using the Real Time PCR method.

Results. A trend towards a decrease in the incidence of registered forms of HCV infection was observed in Nizhny Novgorod from 2016 to 2021. It was found that among the various suspected transmission routes and risk factors for HCV infection, the predominant ones were a history of injected drug used and sexual transmission. The seroprevalence of anti-HCV was 3.6 ± 0.1 % and the prevalence of HCV RNA among the adult population was 1.8 ± 0.1 %. The highest prevalence of active HCV infection was observed in the age groups of 30–39 years (3.3 ± 0.3 %) and 40–49 years (5.7 ± 0.5 %).

Conclusions. To achieve the goals of the HCV elimination program, targeted and dynamic seroepidemiological studies are necessary to increase the number of individuals screened for HCV infection markers, with subsequent expansion of access to effective antiviral therapy for those with active infection.

Keywords

hepatitis C / serological testing / molecular genetic testing / epidemiological surveillance / infection markers

References

[1] WHO. Гепатит С, available at: https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-c.

[2] Pol S., Lagaye S. The remarkable history of the hepatitis C virus. Genes and Immunity 2019; 20: 436–446.

[3] Gower E., Estes C., Blach S. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology 2014; 61: 45–57.

[4] WHO Regional Office for Europe. Action plan for the health sector response to viral hepatitis in the WHO European Region. 2017; 5: 1–45.

[5] Hatzakis A., Chulanov V., Gadano A.C. et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm – Volume 2. Journal of Viral Hepatitis 2015; 22: 26–45.

[6] Han R., Zhou J., François C. et al. Preva-lence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: A systematic review update. BMC Infectious Diseases 2019; 19: 1–14.

[7] Han R., Zhou J., François C. et al. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: A systematic review update. BMC Infectious Diseases 2019; 19: 1–14.

[8] Maaroufi A., Vince A., Himatt S.M. et al. Historical epidemiology of hepatitis C vi-rus in select countries – volume 4. Journal of Viral Hepatitis 2017; 24: 8–24.

[9] Maaroufi A., Vince A., Himatt S.M. et al. Historical epidemiology of hepatitis C virus in select countries – volume 4. Journal of Viral Hepatitis 2017; 24: 8–24.

[10] Hofstraat S.H.I., Falla A.M., Duffell E.F. et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: A systematic review. Epidemiology and Infection 2017; 145: 2873–2885.

[11] Geneva: World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. World Health Organization, Switzerland 2022; 134.

[12] Geneva: World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. World Health Organization. Switzerland 2022; 134.

[13] Blach S., Terrault N.A., Tacke F. et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology & Hepatology 2022; 7: 396–415.

[14] Blach S., Zeuzem S., Manns M. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Lancet Gastroenterology and Hepatology 2017; 2: 161–176.

[15] List of instructions for the implementation of the Message of the President of the Russian Federation to the Federal Assembly of the Russian Federation dated April 21, 2021, available at: http://www.kremlin.ru/acts/assignments/orders/65524 (in Russian).

[16] Перечень поручений по реализации Послания Президента Российской Федерации Федеральному Собранию Российской Федерации от 21 апреля 2021 года, available at: http://www.kremlin.ru/acts/assignments/orders/65524.

[17] Mikhaylov M.I., Yushchuk N.D., Malinnikova E.Yu., Kyuregyan K.K., Isaeva O.V., Znoyko О.О. Klimova E.A. Viral hepatitis as public health problem in the Russian Federation (a design program for the control and elimination of viral hepatitis). Healthcare Management: news, views, education. Bulletin of VSHOUZ 2018; 2: 20–29 (in Russian).

[18] Михайлов М.И., Ющук Н.Д., Малинникова Е.Ю., Кюрегян К.К., Исаева О.В., Знойко О.О., Климова Е.А. Вирусные гепатиты – проблема общественного здоровья в Российской Федерации (проект программы по контролю и ликвидации вирусных гепатитов). Оргздрав: Новости, Мнения, Обучение. Вестник ВШОУЗ 2018; 2: 20–29.

[19] The action plan to combat hepatitis C, available at: http://government.ru/news/46972 (in Russian).

[20] План мероприятий по борьбе с гепатитом С, available at: http://government.ru/news/46972

[21] Soboleva N.V., Carlsen A.A., Kozhanova T.V.et al. Frequency of detection of antibodies to hepatitis C virus among conventionally healthy population of Russian Federation. Zh. Mikrobiol. (Moscow). 2017; 3: 99–106 (in Russian).

[22] Соболева H.В., Карлсен А.А., Кожанова Т.В. и др. Частота выявления антител к вирусу гепатита С среди условно здорового населения Российской Федерации. Журнал микробиологии 2017; 3: 99–106.

[23] Soboleva N.V. The prevalence of hepatitis C virus among the conditionally healthy population of the Russian Federation: abstract. dis. … cand. biol. sciences. Moscow 2020; 25 (in Russian).

[24] Соболева Н.В. Распространенность вируса гепатита С среди условно здорового населения Российской Федерации: автореф. дис. … канд. биол. наук. М. 2020; 25.

[25] Yushchuk N.D., Znojko O.O., Yakushechkina N.A.et al. Assessment of the Socio-Economic Burden of Hepatitis C in the Russian Federation. Epidemiology and vaccinal prevention 2013; 2: 18–33 (in Russian).

[26] Ющук Н.Д., Знойко О.О., Якушечкина Н.А. и др. Оценка социально-экономического бремени гепатита С в Российской Федерации. Эпидемиология и вакцинопрофилактика 2013; 2: 18–33.

[27] On the state of sanitary and epidemiological wellbeing of the population in the Russian Federation in 2022: State Report. Moscow: The Federal Service for the Oversight of Consumer Protection and Welfare 2023; 368 (in Russian).

[28] О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 г.: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека 2023; 368.

RIGHTS & PERMISSIONS

Eco-Vector